A 12-month study to investigate the efficacy, safety and pharmacokinetics of a monthly dosing regimen of ranibizumab (0.5 mg) in combination with pegpleranib (1.5mg), compared to monthly raranibizumab (0.5 mg) monotherapy, in patients with nAMD

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2016 - December 14, 2016